The differential role of PU.1 in normal and malignant haematopoiesis: from master regulator of differentiation to coordinator of leukaemia networks

PU.1在正常和恶性造血中的不同作用:从分化的主调节因子到白血病网络的协调员

基本信息

  • 批准号:
    MR/X008371/1
  • 负责人:
  • 金额:
    $ 100.81万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

The behaviour of cells is determined by the proteins that they contain. This protein composition greatly differs between cell types and even between cells within tissues and explains the different cell behaviours and functions that we observe. The levels of these proteins and why different proteins are present in specific cells are determined by tightly-regulated processes called transcription, where an intermediate product called a transcript is generated from a gene's DNA-template, and translation, where the transcript is then used to assemble the specific protein coded for by that gene. The process of transcription has been well studied in blood formation. Blood is a very complex tissue, containing different specialised cells that carry oxygen, cells that cause the blood to clot and cells that fight infection. However, every cell within the blood is generated from a single source: the haematopoietic stem cell (HSC), with the differing cells maturing and becoming more specialised through an ordered process called differentiation. In general, differentiation is orchestrated by specialised proteins called transcription factors that bind to and regulate the DNA of specific genes whose protein products are necessary for specialisation. The binding of the transcription factors then instruct the generation of transcripts from that gene, resulting in protein expression. The expression of these transcription factors is also tightly controlled and changes through differentiation and specialisation.One of the cardinal features of leukaemias, and most cancers, is that this ordered process of differentiation is blocked and in effect, no specialised mature blood cells are formed. Acute leukaemias, such as Acute Myeloid Leukaemia (AML), are aggressive cancers with a dismal survival rate and are thus an unmet medical need. We have recently discovered that a transcription factor called PU.1 that is usually associated with normal blood differentiation is also absolutely required to maintain AML, a cellular state that lacks differentiation. This project will focus on answering the interesting question of why PU.1 drives differentiation in normal cells yet maintains AML. This seems at first-glance counterintuitive, however we speculate that: 1) differences in levels of the PU.1 protein, 2) differences in its binding to and regulation of different target genes and 3) differences in the proteins that it interacts with and alterations in its structure (called post-translational modifications) between the normal and leukaemia state explain this altered behaviour. We will interrogate these avenues in this proposal, utilising state-of-the-art techniques in relevant model systems and multiple AML patient samples. Moreover, we will target PU.1 and its interaction partners with specific drugs and genetic perturbations to determine if it may be a relevant and safe therapeutic target in patients with AML. Therefore, the likely outcomes of this project are that we will significantly improve our understanding both of leukaemia biology and of the normal differentiation of blood cells, that we will identify PU.1 and its interacting proteins as potential therapeutic targets in AML and potentially that we may suggest an effective therapy in this aggressive disease.
细胞的行为是由它们所含的蛋白质决定的。这种蛋白质组成在细胞类型之间,甚至在组织内的细胞之间存在很大差异,并解释了我们观察到的不同细胞行为和功能。这些蛋白质的水平以及为什么不同的蛋白质存在于特定的细胞中是由严格调控的过程决定的,称为转录,其中称为转录物的中间产物是从基因的DNA模板产生的,以及翻译,其中转录物然后用于组装由该基因编码的特定蛋白质。转录过程在血液形成中已经得到了很好的研究。血液是一种非常复杂的组织,包含不同的携带氧气的专门细胞,导致血液凝结的细胞和抵抗感染的细胞。然而,血液中的每一个细胞都是由一个来源产生的:造血干细胞(HSC),不同的细胞通过一个称为分化的有序过程成熟并变得更加专业化。一般来说,分化是由称为转录因子的专门蛋白质精心策划的,这些转录因子结合并调节特定基因的DNA,其蛋白质产物是专门化所必需的。然后,转录因子的结合指导从该基因产生转录本,导致蛋白质表达。这些转录因子的表达也受到严格控制,并通过分化和特化而发生变化。白血病和大多数癌症的主要特征之一是这种有序的分化过程被阻断,实际上,没有特化的成熟血细胞形成。急性白血病,如急性髓性白血病(AML),是具有令人沮丧的存活率的侵袭性癌症,因此是未满足的医疗需求。我们最近发现,通常与正常血液分化相关的称为PU.1的转录因子也是维持AML(一种缺乏分化的细胞状态)所必需的。该项目将专注于回答为什么PU.1驱动正常细胞分化但维持AML的有趣问题。乍一看,这似乎是违反直觉的,但我们推测:1)PU.1蛋白水平的差异,2)其与不同靶基因的结合和调节的差异,以及3)与正常和白血病状态之间相互作用的蛋白质的差异及其结构的改变(称为翻译后修饰)解释了这种改变的行为。我们将在本提案中探讨这些途径,在相关模型系统和多个AML患者样本中利用最先进的技术。此外,我们将用特定的药物和遗传扰动靶向PU.1及其相互作用伙伴,以确定它是否可能是AML患者的相关和安全的治疗靶点。因此,该项目的可能结果是,我们将显着提高我们对白血病生物学和血细胞正常分化的理解,我们将确定PU.1及其相互作用蛋白作为AML的潜在治疗靶点,并且我们可能建议这种侵袭性疾病的有效治疗。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.
  • DOI:
    10.1016/j.xgen.2023.100426
  • 发表时间:
    2023-12-13
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Isobe, Tomoya;Kucinski, Iwo;Barile, Melania;Wang, Xiaonan;Hannah, Rebecca;Bastos, Hugo P.;Chabra, Shirom;Vijayabaskar, M. S.;Sturgess, Katherine H. M.;Williams, Matthew J.;Giotopoulos, George;Marando, Ludovica;Li, Juan;Rak, Justyna;Gozdecka, Malgorzata;Prins, Daniel;Shepherd, Mairi S.;Watcham, Sam;Green, Anthony R.;Kent, David G.;Vassiliou, George S.;Huntly, Brian J. P.;Wilson, Nicola K.;Gottgens, Berthold
  • 通讯作者:
    Gottgens, Berthold
A guide to epigenetics in leukaemia stem cells.
  • DOI:
    10.1002/1878-0261.13544
  • 发表时间:
    2023-12
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Agrawal-Singh, Shuchi;Bagri, Jaana;Sakakini, Nathalie;Huntly, Brian J. P.
  • 通讯作者:
    Huntly, Brian J. P.
In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis.
  • DOI:
    10.1038/s41588-023-01471-2
  • 发表时间:
    2023-09
  • 期刊:
  • 影响因子:
    30.8
  • 作者:
    Lara-Astiaso, David;Goni-Salaverri, Ainhoa;Mendieta-Esteban, Julen;Narayan, Nisha;Del Valle, Cynthia;Gross, Torsten;Giotopoulos, George;Beinortas, Tumas;Navarro-Alonso, Mar;Aguado-Alvaro, Laura Pilar;Zazpe, Jon;Marchese, Francesco;Torrea, Natalia;Calvo, Isabel A.;Lopez, Cecile K.;Alignani, Diego;Lopez, Aitziber;Saez, Borja;Taylor-King, Jake P.;Prosper, Felipe;Fortelny, Nikolaus;Huntly, Brian J. P.
  • 通讯作者:
    Huntly, Brian J. P.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian Huntly其他文献

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone
  • DOI:
    10.1182/blood-2023-185798
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Adam J Mead;Claire N Harrison;Brian Huntly;Bethan Psaila;Rebecca Boucher;Sonia Fox;Louise Hopkins;Joseph Rogers;Charlotte Gaskell;Amit Patel
  • 通讯作者:
    Amit Patel
1002 - LOOPING AND LEUKAEMIA: ALTERATIONS IN DNA TOPOLOGY SHAPE MALIGNANT TRANSCRIPTIONAL PROGRAMMES
  • DOI:
    10.1016/j.exphem.2019.06.240
  • 发表时间:
    2019-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Brian Huntly
  • 通讯作者:
    Brian Huntly
Hijacking of the Fibrinolytic System By B-Cell Acute Lymphoblastic Leukaemia and Its Therapeutic Targeting
  • DOI:
    10.1182/blood-2023-178811
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Valentina Minciacchi;Christina Karantanou;Costanza Zanetti;Rahul Kumar;Theresa Krack;Nathalie Thomasberger;Pablo Llavona;Sylvia Hartmann;Veronique Maguer-Satta;Sylvain Lefort;Mateusz Putyrski;Andreas Ernst;Eshwar Meduri;Brian Huntly;Wolfram Ruf;Daniela S. Krause
  • 通讯作者:
    Daniela S. Krause
2008 – INTEGRATIVE SINGLE-CELL ANALYSIS OF PRELEUKAEMIC MUTANT MOUSE MODELS ILLUSTRATES MUTATION-SPECIFIC HAEMATOPOIETIC PERTURBATIONS
  • DOI:
    10.1016/j.exphem.2022.07.040
  • 发表时间:
    2022-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tomoya Isobe;Iwo Kucinski;Xiaonan Wang;Melania Barile;Rebecca Hannah;George Giotopoulos;Sarah Horton;Ludovica Marando;Juan Li;Justyna Rak;Malgorzata Gozdecka;Meng Wang;Daniel Prins;Hyun Jung Park;Sam Watcham;Ketan Patel;Anthony Green;David Kent;George Vassiliou;Brian Huntly
  • 通讯作者:
    Brian Huntly
A SINGLE CELL STUDY OF LYMPHOMA EVOLUTION
  • DOI:
    10.1016/j.exphem.2019.06.321
  • 发表时间:
    2019-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah Horton;Shabana Vohra;Pedro Madrigal;Nicola Wilson;Bertie Gottgens;Brian Huntly
  • 通讯作者:
    Brian Huntly

Brian Huntly的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian Huntly', 18)}}的其他基金

Stroboscopic opto-acoustic scattering (SOAS) flow cytometer for pre-cancerous detection
用于癌前检测的频闪光声散射 (SOAS) 流式细胞仪
  • 批准号:
    BB/X003620/1
  • 财政年份:
    2023
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Research Grant
Elucidation of cellular and molecular mechanisms of lymphoma induction and evolution to identify therapeutic targets
阐明淋巴瘤诱导和进化的细胞和分子机制以确定治疗靶点
  • 批准号:
    MR/R009708/1
  • 财政年份:
    2018
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Research Grant
Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)
急性髓系白血病 (AML) 异常增强子功能的表征和靶向
  • 批准号:
    MR/M010392/1
  • 财政年份:
    2015
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Research Grant

相似国自然基金

PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
  • 批准号:
    82372275
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
  • 批准号:
    82371070
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目

相似海外基金

Direct chemical control of the hematopoietic master transcription factor PU.1
造血主转录因子 PU.1 的直接化学控制
  • 批准号:
    10540346
  • 财政年份:
    2021
  • 资助金额:
    $ 100.81万
  • 项目类别:
Direct chemical control of the hematopoietic master transcription factor PU.1
造血主转录因子 PU.1 的直接化学控制
  • 批准号:
    10322390
  • 财政年份:
    2021
  • 资助金额:
    $ 100.81万
  • 项目类别:
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
开发 PU.1 抑制调节剂作为阿尔茨海默病的新疗法
  • 批准号:
    10435506
  • 财政年份:
    2020
  • 资助金额:
    $ 100.81万
  • 项目类别:
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
开发 PU.1 抑制调节剂作为阿尔茨海默病的新疗法
  • 批准号:
    10159826
  • 财政年份:
    2020
  • 资助金额:
    $ 100.81万
  • 项目类别:
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
开发 PU.1 抑制调节剂作为阿尔茨海默病的新疗法
  • 批准号:
    10642872
  • 财政年份:
    2020
  • 资助金额:
    $ 100.81万
  • 项目类别:
The role of PU.1 on lipid metabolism and cell cycle regulation in myeloid progenitor cells
PU.1对骨髓祖细胞脂质代谢和细胞周期调节的作用
  • 批准号:
    510961-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Pivotal role of PU.1 and Spi-B in B cell acute lymphoblastic leukemia and lymphoma
PU.1和Spi-B在B细胞急性淋巴细胞白血病和淋巴瘤中的关键作用
  • 批准号:
    320424
  • 财政年份:
    2015
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Operating Grants
Role of PU.1 suppressive target gene, metallothionein, as a forecasting biomarker for anticancer agents
PU.1 抑制靶基因金属硫蛋白作为抗癌药物预测生物标志物的作用
  • 批准号:
    26460685
  • 财政年份:
    2014
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Osmotic responsiveness of the master immune regulator PU.1
主免疫调节剂 PU.1 的渗透反应性
  • 批准号:
    8770311
  • 财政年份:
    2014
  • 资助金额:
    $ 100.81万
  • 项目类别:
The Role of PU.1 in Homeostasis and Function of Brain Macrophages
PU.1 在脑巨噬细胞稳态和功能中的作用
  • 批准号:
    165157194
  • 财政年份:
    2010
  • 资助金额:
    $ 100.81万
  • 项目类别:
    Research Units
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了